Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Frilling

Showing results (41-50 of 144) with videos related to

Pageof 15
Sort By:
Endocrine-Related Cancer|May 31, 2012
Neuroendocrine tumor disease: an evolving landscapeAndrea Frilling, Goran Akerström, Massimo Falconi, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 20, 2002
Right-liver living donor transplantation for decompensated end-stage liver diseaseGiuliano Testa, Massimo Malagó, Silvio Nadalin, et al.
European Radiology|November 16, 2007
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancerLutz S Freudenberg, Andrea Frilling, Hilmar Kühl, et al.
Hellenic Journal of Nuclear Medicine|February 14, 2015
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitoninKathryn Tran, Sairah Khan, Mina Taghizadehasl, et al.
Neuroendocrinology|April 1, 2015
Incidence of Second Primary Malignancies in Patients with Neuroendocrine TumoursAshley K Clift, Panagiotis Drymousis, Adil Al-Nahhas, et al.
Annals of Surgery|June 29, 2021
Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% AccuracyIrvin M Modlin, Mark Kidd, Andrea Frilling, et al.
Surgery|December 26, 2006
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumorsAndrea Frilling, Frank Weber, Fuat Saner, et al.
Langenbeck'S Archives of Surgery|February 19, 2010
Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCCFrank Simon, Maximilian Bockhorn, Christian Praha, et al.
Gut|June 15, 2007
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumourFlorian Grabellus, Peter Ebeling, Karl Worm, et al.
Neuroendocrinology|January 31, 2019
Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)John K Ramage, Pankaj Punia, Olusola Faluyi, et al.
Pageof 15

Showing results (41-50 of 144) with videos related to

Sort By:
Pageof 15
Endocrine-Related Cancer|May 31, 2012
Neuroendocrine tumor disease: an evolving landscapeAndrea Frilling, Goran Akerström, Massimo Falconi, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 20, 2002
Right-liver living donor transplantation for decompensated end-stage liver diseaseGiuliano Testa, Massimo Malagó, Silvio Nadalin, et al.
European Radiology|November 16, 2007
Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancerLutz S Freudenberg, Andrea Frilling, Hilmar Kühl, et al.
Hellenic Journal of Nuclear Medicine|February 14, 2015
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitoninKathryn Tran, Sairah Khan, Mina Taghizadehasl, et al.
Neuroendocrinology|April 1, 2015
Incidence of Second Primary Malignancies in Patients with Neuroendocrine TumoursAshley K Clift, Panagiotis Drymousis, Adil Al-Nahhas, et al.
Annals of Surgery|June 29, 2021
Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% AccuracyIrvin M Modlin, Mark Kidd, Andrea Frilling, et al.
Surgery|December 26, 2006
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumorsAndrea Frilling, Frank Weber, Fuat Saner, et al.
Langenbeck'S Archives of Surgery|February 19, 2010
Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCCFrank Simon, Maximilian Bockhorn, Christian Praha, et al.
Gut|June 15, 2007
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumourFlorian Grabellus, Peter Ebeling, Karl Worm, et al.
Neuroendocrinology|January 31, 2019
Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)John K Ramage, Pankaj Punia, Olusola Faluyi, et al.
Pageof 15